KDR
MOLECULAR TARGETkinase insert domain receptor
KDR (kinase insert domain receptor) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KDR
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Sorafenib | 4.74 | 114 |
| 2 | Axitinib | 2.56 | 12 |
| 3 | Quercetin | 1.10 | 2 |
| 4 | Avapritinib | 0.69 | 1 |
| 5 | Crizotinib | 0.69 | 1 |
| 6 | Dasatinib | 0.69 | 1 |
| 7 | kenpaullone | 0.69 | 1 |
| 8 | sp600125 | 0.69 | 1 |
| 9 | tyrphostin ag 1295 | 0.69 | 1 |
| 10 | Vemurafenib | 0.69 | 1 |
About KDR as a Drug Target
KDR (kinase insert domain receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented KDR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KDR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.